KPTI - Karyopharm's selinexor shows promising results in COVID-19 and Low LDH/DD

Karyopharm Therapeutics (KPTI) presents data from a Phase 2 clinical study evaluating low dose oral selinexor in hospitalized patients with severe COVID-19 at the International Society for Influenza and Other Respiratory Virus Diseases Antiviral Group Virtual Conference on Therapeutics for COVID-19 taking place from October 6 - 8, 2020.While an interim analysis indicated that the trial was unlikely to meet its pre-specified primary endpoint, and has since been discontinued, the results demonstrated encouraging anti-viral and anti-inflammatory activity in an important subset of treated patients.The placebo-controlled Phase 2 study was designed to assess the activity and safety of 20mg of selinexor given orally three times a week for two weeks, a dosing level lower than the FDA approved dose of selinexor, marketed as XPOVIO, to treat patients with relapsed or refractory multiple myeloma or relapsed or refractory diffuse large B-cell lymphoma.A post-hoc analysis of 66 patients with either baseline serum lactate dehydrogenase ((LDH)) ?370

For further details see:

Karyopharm's selinexor shows promising results in COVID-19 and Low LDH/DD